Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer

David R. Spigel, Thomas J. Ervin, Rodryg A. Ramlau, Davey B. Daniel, Jerome H. Goldschmidt, George R. Blumenschein, Maciej J. Krzakowski, Gilles Robinet, Benoit Godbert, Fabrice Barlesi, Ramaswamy Govindan, Taral Patel, Sergey V. Orlov, Michael S. Wertheim, Wei Yu, Jiping Zha, Robert L. Yauch, Premal H. Patel, See Chun Phan, Amy C. Peterson